Board Member
Agios Pharmaceuticals, Inc. (AGIO)Equibles does not estimate personal net worth.
Get an email with a short summary when Agios Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get AGIO alertsBrian Goff is recorded as Board Member and CEO at Agios Pharmaceuticals, Inc. (AGIO). The newest filing on record that lists Brian Goff as Board Member and CEO at Agios Pharmaceuticals, Inc. (AGIO) is dated April 24, 2026. Agios Pharmaceuticals, Inc. reported in an 8-K filed June 18, 2026 that Brian Goff was appointed Class I director, effective June 18, 2026. Agios Pharmaceuticals, Inc. reported in an 8-K filed June 14, 2023 that Brian Goff was appointed Class I director, effective June 13, 2023. The proxy statement of Agios Pharmaceuticals, Inc. reports total compensation of $5,370,389 for Brian Goff in fiscal 2025, including a base salary of $846,864. Disclosed compensation is on record for 6 fiscal years. Brian Goff has spoken on 15 earnings calls and 6 other investor events across 1 company, most recently for Agios Pharmaceuticals, Inc. on September 9, 2026. Agios Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Agios Pharmaceuticals, Inc. includes Jacqualyn Fouse (CEO and Board Member), David P. Schenkein (Chairman), Jacqualyn A. Fouse (Chairman) and 7 others.
“The Company's stockholders elected Rahul Ballal, Ph.D., Brian Goff and Cynthia Smith as Class I directors, each to serve for a three-year term expiring at the 2029 Annual Meeting of Stockholders and until his or her successor has been duly elected and qualified.”
“The Company's stockholders elected Rahul Ballal, Brian Goff and Cynthia Smith as Class I directors, each to serve for a three-year term expiring at the 2026 Annual Meeting of Stockholders and until his or her successor has been duly elected and qualified.”
“Before we review our second quarter results, I'd like to take a step back and highlight the strong position from which Agios is executing as we continue advancing toward our goal of building a multi-billion dollar rare disease business.”
“Before we review our second quarter results, I'd like to take a step back and highlight the strong position from which Agios is executing as we continue advancing toward our goal of building a multi-billion dollar rare disease business.”
“We appreciate you being here and are excited to share new data presented this weekend at the 2026 EHA Congress here in Stockholm, strengthening the profile of Mitipivet across thalassemia and sickle cell disease.”
“We appreciate you being here and are excited to share new data presented this weekend at the 2026 EHA Congress here in Stockholm, strengthening the profile of Mitipivet across thalassemia and sickle cell disease.”
“And thanks, everyone, for tuning in and listening to the exciting Agios story. It has been a really great start to 2026 for us with, as you just noted, a lot to talk about.”
Start not stated–present
Last confirmed April 24, 2026
Start not stated–present
Last confirmed April 24, 2026
Biotechnology · Healthcare
Board Member, CEO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Agios Pharmaceuticals, Inc. (AGIO) | Chief Executive Officer | $846,864 | $5,370,389 |
| 2024 | Agios Pharmaceuticals, Inc. (AGIO) | Chief Executive Officer | $822,198 | $6,776,359 |
| 2023 | Agios Pharmaceuticals, Inc. (AGIO) | Chief Executive Officer | $798,250 | $3,416,453 |
| 2022 | Agios Pharmaceuticals, Inc. (AGIO) | Chief Executive Officer | $308,239 | $11,744,447 |
| 2021 | Agios Pharmaceuticals, Inc. (AGIO) | Chief Executive Officer | — | — |
| 2020 | Agios Pharmaceuticals, Inc. (AGIO) | Chief Executive Officer | — | — |
